[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
July 16, 2019

Clarification of Reporting of Potential Conflicts of Interest in JAMA Articles

Author Affiliations
  • 1National Academy of Medicine, Washington, DC
JAMA. 2019;322(7):696. doi:10.1001/jama.2019.11051

To the Editor I am writing to provide additional information to clarify conflict of interest disclosures in articles I published in JAMA in 2014, 2016, and 2019.

In February 2014, I was selected to become the president of the Institute of Medicine, now known as the National Academy of Medicine (NAM). Between that time and July 1, 2014, my first day of service, I resigned all positions and relationships with industry and sold health care–related stocks to eliminate all potential financial conflicts of interest. Prior to becoming president of the Institute of Medicine, I was a member of the board of directors of Medtronic Inc and Alnylam Pharmaceuticals Inc. As previously disclosed to and approved by NAM, I have received deferred stock compensation for past board services prior to July 2014. Because Medtronic makes a device that could be used to treat or manage pain, and because Alnylam makes products for targeted gene therapy, in the spirit of transparency and abundance of caution, it would have been helpful for those past relationships to have been disclosed.